MD considers funds for growing nano-biotech field

Maryland lawmakers are considering a bill that could pump between $5 million and $10 million next year into a program to support the development of nano-biotech companies. Nanotechnology, the science of the very small, has increasingly been a focus of researchers exploring new ways to develop and deliver therapies. Maryland, the home to leading research groups operating close to Washington D.C., hopes that a relatively small amount of money could have a big impact on its efforts to attract researchers and new biotech businesses to the state.

"This investment will enable our state to bring the best talent to Maryland to build on our current strength to leverage new grants," William Kirwan, chancellor of the University System of Maryland, told the AP.

- read the AP report

Suggested Articles

Across its 15-year history, Omega Funds has a hand in a clutch of high-profile biotechs such as Editas Medicine and Juno Therapeutics.

After Novartis’ near $10 billion buyout of The Medicines Company, many thought cardiovascular therapies were hot again.

The data position Leo to file for approval of the Dupixent rival in atopic dermatitis next year.